Position paper of the Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), and the Italian Study Group of Diabetes in pregnancy: Metformin use in pregnancy.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9200299 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-5233 (Electronic) Linking ISSN: 09405429 NLM ISO Abbreviation: Acta Diabetol Subsets: MEDLINE
    • Publication Information:
      Publication: Berlin : Springer Verlag
      Original Publication: Berlin : Springer International, c1991-
    • Subject Terms:
      Metformin*/therapeutic use ; Metformin*/pharmacology ; Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/epidemiology ; Diabetes Mellitus, Type 2*/complications ; Diabetes, Gestational*/drug therapy ; Diabetes, Gestational*/epidemiology ; Polycystic Ovary Syndrome*/complications ; Polycystic Ovary Syndrome*/drug therapy; Pregnancy ; Infant, Newborn ; Child ; Female ; Humans ; Hypoglycemic Agents/therapeutic use ; Hypoglycemic Agents/pharmacology ; Obesity/complications ; Obesity/drug therapy ; Obesity/epidemiology
    • Abstract:
      Objective: This document purpose is to create an evidence-based position statement on the role of metformin therapy in pregnancy complicated by obesity, gestational diabetes (GDM), type 2 diabetes mellitus (T2DM), polycystic ovary syndrome (PCOS) and in women undergoing assisted reproductive technology (ART).
      Methods: A comprehensive review of international diabetes guidelines and a search of medical literature was performed to identify studies presenting data on the use of metformin in pregnancy. The document was approved by the councils of the two scientific societies.
      Results: In condition affecting the fertility, as PCOS, metformin use in pre-conception or early in pregnancy may be beneficial for clinical pregnancy, even in ART treatment, and in obese-PCOS women may reduce preterm delivery. In obese women, even in the presence of GDM or T2DM, metformin use in pregnancy is associated with a lower gestational weight gain. In pregnancy complicated by diabetes (GDM or T2DM), metformin improves maternal glycemic control and may reduce insulin dose. Neonatal and infant outcomes related to metformin exposure in utero are lacking. Metformin use in women with GDM or T2DM is associated with lower birth weight. However, an increased tendency to overweight-obesity has been observed in children, later in life.
      Conclusions: Metformin may represent a therapeutic option in selected women with obesity, PCOS, GDM, T2DM, and in women undergoing ART. However, more research is required specifically on the long-term effects of in utero exposition to metformin.
      (© 2023. The Author(s).)
    • References:
      Diabetes Metab Res Rev. 2014 Jan;30(1):23-30. (PMID: 23983188)
      JAMA Pediatr. 2019 Feb 1;173(2):160-168. (PMID: 30508164)
      PLoS One. 2016 Sep 28;11(9):e0163805. (PMID: 27681875)
      Fertil Steril. 2011 Dec;96(6):1384-1390.e4. (PMID: 21982727)
      Hum Reprod. 2004 Aug;19(8):1734-40. (PMID: 15178665)
      Pediatr Res. 2011 Feb;69(2):175-80. (PMID: 21076366)
      N Engl J Med. 2008 May 8;358(19):2003-15. (PMID: 18463376)
      Pediatr Obes. 2023 Jan;18(1):e12974. (PMID: 36093602)
      Regul Toxicol Pharmacol. 2018 Feb;92:324-332. (PMID: 29291990)
      Lancet Diabetes Endocrinol. 2019 Apr;7(4):256-266. (PMID: 30792154)
      N Engl J Med. 2016 Feb 4;374(5):434-43. (PMID: 26840133)
      Am J Perinatol. 2015 Feb;30(2):163-70. (PMID: 24896141)
      BMJ. 2018 Jun 25;361:k2477. (PMID: 29941493)
      Gynecol Endocrinol. 2022 Dec;38(12):1035-1046. (PMID: 36285403)
      Drug Metab Dispos. 2010 May;38(5):833-40. (PMID: 20118196)
      Int J Mol Sci. 2021 May 28;22(11):. (PMID: 34071182)
      PLoS One. 2015 May 06;10(5):e0125712. (PMID: 25945500)
      Eur J Obstet Gynecol Reprod Biol. 2008 Jan;136(1):29-33. (PMID: 17350747)
      Crit Rev Anal Chem. 2018 Jan 2;48(1):66-72. (PMID: 28892402)
      Ther Drug Monit. 2006 Feb;28(1):67-72. (PMID: 16418696)
      J Clin Endocrinol Metab. 2010 Dec;95(12):E448-55. (PMID: 20926533)
      Diabetes Care. 2022 Jul 7;45(7):1532-1539. (PMID: 35671033)
      J Coll Physicians Surg Pak. 2013 Dec;23(12):866-9. (PMID: 24304990)
      Lancet Diabetes Endocrinol. 2023 Mar;11(3):191-202. (PMID: 36746160)
      Lancet Diabetes Endocrinol. 2020 Oct;8(10):834-844. (PMID: 32946820)
      Obstet Gynecol. 2005 Jun;105(6):1437-41. (PMID: 15932841)
      Lancet Diabetes Endocrinol. 2015 Oct;3(10):778-86. (PMID: 26165398)
      Clin Pharmacol Ther. 2003 Jan;73(1):71-7. (PMID: 12545145)
      Diabetes Care. 2022 Jan 1;45(Suppl 1):S232-S243. (PMID: 34964864)
      BMJ Open Diabetes Res Care. 2018 Apr 13;6(1):e000456. (PMID: 29682291)
      BMJ. 2006 Jun 24;332(7556):1485. (PMID: 16769748)
      Reprod Biol Endocrinol. 2022 Feb 7;20(1):30. (PMID: 35130922)
      Lancet Child Adolesc Health. 2019 Mar;3(3):166-174. (PMID: 30704873)
      Hum Reprod. 2006 Jun;21(6):1416-25. (PMID: 16501038)
      J Diabetes Res. 2015;2015:325851. (PMID: 25874236)
      J Clin Endocrinol Metab. 2018 Apr 1;103(4):1612-1621. (PMID: 29490031)
      Cochrane Database Syst Rev. 2020 Dec 21;12:CD006105. (PMID: 33347618)
      Clin Endocrinol (Oxf). 2022 Aug;97(2):227-236. (PMID: 35383999)
      Diabet Med. 2017 Jan;34(1):27-36. (PMID: 27150509)
      Hum Reprod Update. 2016 Nov;22(6):687-708. (PMID: 27511809)
      Diabetes Care. 2011 Oct;34(10):2279-84. (PMID: 21949222)
      Endocr Rev. 2021 Jan 28;42(1):77-96. (PMID: 32897388)
      Arch Gynecol Obstet. 2019 May;299(5):1295-1303. (PMID: 30953188)
      BMJ Open Diabetes Res Care. 2022 Jan;10(1):. (PMID: 34987051)
      BMJ. 2011 Oct 13;343:d6309. (PMID: 21998337)
      Lancet. 2002 May 11;359(9318):1690-2. (PMID: 12020549)
      Fertil Steril. 2008 Mar;89(3):505-22. (PMID: 18243179)
      J Dev Orig Health Dis. 2022 Jun;13(3):390-394. (PMID: 34134812)
      Lancet Diabetes Endocrinol. 2019 Jan;7(1):15-24. (PMID: 30528218)
      Hum Reprod. 2020 Aug 1;35(8):1914-1921. (PMID: 32644124)
      Diabetologia. 2017 Sep;60(9):1662-1667. (PMID: 28770326)
      N Engl J Med. 2022 Jul 21;387(3):248-259. (PMID: 35857661)
      Clin Sci (Lond). 2012 Mar;122(6):253-70. (PMID: 22117616)
      Diabetes Care. 2020 Feb;43(2):487-493. (PMID: 31857443)
      Hum Reprod Update. 2006 Nov-Dec;12(6):673-83. (PMID: 16891296)
      Diabetologia. 2017 Sep;60(9):1612-1619. (PMID: 28770325)
      Medicine (Baltimore). 2017 Sep;96(39):e8183. (PMID: 28953677)
      J Obstet Gynaecol Res. 2021 Dec;47(12):4148-4157. (PMID: 34571574)
      Biol Reprod. 2013 Mar 07;88(3):55. (PMID: 23303678)
      Cochrane Database Syst Rev. 2018 Jul 24;7:CD010564. (PMID: 30039871)
      Am J Perinatol. 2013 Jun;30(6):483-90. (PMID: 23096052)
      Diabetologia. 2002 Nov;45(11):1509-14. (PMID: 12436333)
      N Engl J Med. 2007 Feb 8;356(6):551-66. (PMID: 17287476)
      Cell Metab. 2014 Dec 2;20(6):953-66. (PMID: 25456737)
      PLoS Med. 2019 Aug 6;16(8):e1002848. (PMID: 31386659)
      Circ Res. 2016 Aug 19;119(5):652-65. (PMID: 27418629)
      Diabet Med. 2022 Mar;39(3):e14700. (PMID: 34569082)
    • Contributed Indexing:
      Keywords: Gestational diabetes; Neonatal outcomes; Obesity; Placenta; Polycystic ovary syndrome; Type 2 diabetes
    • Accession Number:
      9100L32L2N (Metformin)
      0 (Hypoglycemic Agents)
    • Publication Date:
      Date Created: 20230704 Date Completed: 20230823 Latest Revision: 20230824
    • Publication Date:
      20231215
    • Accession Number:
      PMC10442287
    • Accession Number:
      10.1007/s00592-023-02137-5
    • Accession Number:
      37401946